Industry context
Notice: trader_wma(): invalid value '1', expected a value between 2 and 100000 in /home/getagraph/public_html/AAA/app/Services/StockChartDataService.php on line 250
BridgeBio Oncology [BBOT]
Last Updated 24 Jun 2026 @ 16:00 (Exchange is closed)
Last: $7.44
-0.80%
-4.08 (↑)
GaG Algo Score™
v1.0
Short
-4.08 (↑)
Medium
-5.74 (↑)
Long
-5.42 (↑)
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 20.24% | 19.95% | 7.04% |
| Loss % | -18.41% | -19.07% | 3.76% |
| Duration | 14.6d | 15d | 8.9d |
| Total Pivots Found | 21 |
| Gain/Loss Legs | 20 (10 Gain / 10 Loss) |
| Last Pivot | Bottom @ $7.12 on 2026-06-10 |
| Change since Last Pivot | $0.32 (4.49%) |
Next Pivot Prediction Last: $7.44
| Predicted Next Type | Top |
| Predicted Price (Avg) | $8.56 |
| Predicted Price (Median) | $8.54 |
| Predicted Price Range (~68%) | $8.06 - $9.06 |
| Change to Avg Target | $1.12 (15.07%) |
| Predicted Date (Avg) | 2026-06-24 |
| Predicted Date Range (~68%) | 2026-06-15 - 2026-07-03 |
| Basis | Based on 10 historical gains (Avg: 20.24%, Median: 19.95%, StdDev: 7.04%) and duration (Avg: 14.6 days, StdDev: 8.9 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
BridgeBio Oncology lost modestly, down -0.80%.
BridgeBio Oncology (BBOT) stock price lost some ground on Wednesday after the stock fell $-0.0600 (-0.80%) from the previous session on below-average volume. The stock fell slightly more than the NASDAQ which was down -0.43%. With 357 673 shares traded, volume yesterday reached $2.66M. This was 448 028 shares less than the prior day. Compared to the 10-day average of 683 920 shares, volume was less than the average.
BridgeBio Oncology signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Strong Bearish Consensus: A significant wave of negative pressure is evident across all time horizons. Technical indicators are decisively bearish in the short-term (17/30, net -50%), medium-term (17/30, net -50%), and long-term (17/30, net -50%), signaling a robust and sustained downtrend.
BridgeBio Oncology Support & Resistance Levels
The stock is trading above the closest support level at $7.40. approximately $0.0400 (0.54%) away. This suggests it is currently acting as a floor, pushing down towards support.The sup dis das support s17.4 -
BridgeBio Oncology Evaluation
- Short score: -4.08
- Medium score: -5.74
- Long score: -5.42
Ownership flow
GetAGraph InsiderPower
Transactions
135
Buy power
475.07M
Sell power
36.87M
Reliability
100/100
Buy / sell
12.88
Hist. corr.
0.26
Latest signal
Buy 2026-05-27
Officer 64
Director 49
Other 10
Major holder 8
2026-06-16
Tipirneni Praveen P. Director
Buy 31 675
2026-06-16
Mccormick Frank Director
Buy 31 675
2026-06-16
Lebowitz Peter F Director
Buy 7 289
2026-06-16
Kelleher Raymond J. Director
Buy 31 675
2026-06-16
Chen Bihua Director
Buy 31 675
2026-06-16
Bauer Jake Director
Buy 31 675
Relationship map
Correlation snapshot
Event context
Volume and dividends
Long volume corr.
-0.24
Short volume corr.
0.04
Positioning pressure
Short interest pressure
Short interest
4.83%
Of outstanding shares
Short float
100.00%
Of tradable float
Days to cover
8.33
Short interest divided by average volume
Squeeze probability
100.00%
+18.05% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Analyst view
Analyst targets
Consensus
$22.00
Median
$23.00
Low
$18.00
High
$24.00
News flow
Latest company news
Market coverage
globenewswire.com BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress May 12, 2026 globenewswire.com BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 12, 2026 247wallst.com Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More May 11, 2026 globenewswire.com BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 Apr 22, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Currency
USD
BridgeBio Oncology Therapeutics functions as a clinicalstage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments These therapies are aimed at combating malignancies driven by RAS and PI3K both frequently encountered oncogenes in human cancers Initially established as an offshoot of BridgeBio Pharma the company concentrates on precision oncology Its developmental pipeline features several promising programs including BBO8520 BBO10203 and BBO11818 all specifically designed to modulate the KRAS and PI3K pathways The company recently became publicly traded through a business combination with Helix Acquisition Corp II This strategic move successfully raised approximately 450 million which will be utilized to further its clinical development initiatives The leadership team comprises Dr Eli Wallace as Chief Executive Officer and Dr Pedro Beltran as Chief Scientific Officer
Navigation